METUBINE IODIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for METUBINE IODIDE (METUBINE IODIDE).
Nondepolarizing neuromuscular blocking agent; competitively binds to nicotinic acetylcholine receptors at the motor endplate, preventing acetylcholine from inducing depolarization and muscle contraction.
| Metabolism | Primarily hydrolyzed by plasma cholinesterases (pseudocholinesterase); also undergoes non-enzymatic hydrolysis at physiologic pH. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 70-80% over 24 hours); biliary/fecal excretion accounts for <10%. |
| Half-life | Terminal elimination half-life: approximately 2-3 minutes (due to rapid redistribution from plasma to tissues), with a longer terminal phase (30-60 minutes) reflecting slow efflux from deep compartments. |
| Protein binding | Approximately 30-40% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 0.3-0.6 L/kg, indicating distribution primarily in extracellular fluid. |
| Bioavailability | Intravenous: 100%; intramuscular: approximately 80-90% (due to rapid absorption); oral: negligible (not administered orally due to poor absorption and first-pass metabolism). |
| Onset of Action | Intravenous: 30-60 seconds; intramuscular: 2-4 minutes. |
| Duration of Action | Intravenous: 5-10 minutes (clinical neuromuscular blockade); intramuscular: 10-30 minutes. |
0.1-0.3 mg/kg IV as a single dose for neuromuscular blockade during surgery. Additional doses of 0.03-0.05 mg/kg at 25-30 minute intervals as needed.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 20-30%; GFR 15-29 mL/min: reduce dose by 40-50%; GFR <15 mL/min: avoid use or use with extreme caution at 50% of normal dose. |
| Liver impairment | Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use due to prolonged duration and risk of accumulation. |
| Pediatric use | Infants and children: 0.2-0.4 mg/kg IV as a single dose; maintenance: 0.04-0.1 mg/kg every 20-30 minutes as needed. |
| Geriatric use | Reduce dose by 30-50% due to increased sensitivity and prolonged duration; monitor renal function closely; consider lower initial doses (0.05-0.15 mg/kg). |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for METUBINE IODIDE (METUBINE IODIDE).
| Breastfeeding | No human data available; M/P ratio unknown. Metubine iodide is expected to be excreted in breast milk in negligible amounts due to high molecular weight and ionization; however, potential for infant oral absorption is low due to poor gastrointestinal bioavailability. Caution advised; consider temporary discontinuation of breastfeeding after administration if maternal benefit outweighs risk. |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Non-depolarizing neuromuscular blocking agents cross the placenta minimally; no well-controlled studies in pregnant women. Animal studies have shown no evidence of teratogenicity but may cause decreased fetal weight and delayed ossification at high doses. Second and third trimesters: Use only if clearly needed; may cause transient fetal hypotonia if used near term. Risk of adverse fetal effects is considered low due to poor placental transfer. |
■ FDA Black Box Warning
Should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards. Facilities for intubation, artificial respiration, oxygen therapy, and reversal agents must be immediately available.
| Serious Effects |
["Hypersensitivity to metubine iodide or any component","Known sensitivity to iodides"]
| Precautions | ["Risk of prolonged neuromuscular block in patients with impaired renal or hepatic function","Potential for histamine release leading to hypotension and bronchospasm","Use with caution in patients with myasthenia gravis, electrolyte disorders, or those receiving other neuromuscular blocking agents"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal vital signs, oxygen saturation, and neuromuscular function (train-of-four monitoring) during use. Fetal heart rate monitoring if used during cesarean section or late pregnancy. Assess for maternal respiratory depression and need for ventilatory support. Post-delivery, monitor neonate for signs of neuromuscular blockade (weak cry, hypotonia, respiratory effort) if drug was administered near delivery. |
| Fertility Effects | No specific human studies on fertility. In animal studies, no adverse effects on fertility or reproductive performance were observed at clinically relevant doses. Theoretical risk of transient neuromuscular effects during conception unlikely due to short duration of action and rapid elimination. |